Question · Q1 2015
Keay Thomas Nakae from Chardan Capital Markets, LLC inquired about the specific mechanisms of the company's stem cells in dry AMD, the reasons for the Phase II trial's delay, potential protocol changes like increasing sample size, the number of participating trial sites, and the completeness of patient follow-up data for the upcoming ISSCR presentation.
Answer
Chief Medical Officer Dr. Stephen Huhn detailed that the cells likely have a multi-factorial mechanism, including phagocytosis and secreting trophic factors to support photoreceptors. He attributed the trial delay to careful protocol planning and confirmed the design includes an interim analysis to potentially adjust sample size. CEO Martin M. McGlynn and Dr. Huhn confirmed approximately 21 sites are planned and that full 12-month follow-up data would be analyzed for the ISSCR presentation.